Publications
664 results found
Chouaid C, Girard N, Kron A, et al., 2022, AMIVANTAMAB VERSUS REAL-WORLD CLINICAL PRACTICE IN EUROPE AND THE US FOR PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER WITH ACTIVATING EPIDERMAL GROWTH FACTOR RECEPTOR EXON 20 INSERTION MUTATIONS, Publisher: ELSEVIER SCIENCE INC, Pages: S32-S32, ISSN: 1098-3015
Aguilar-Duran S, Mee J, Popat S, et al., 2022, Atezolizumab-induced linear IgA bullous dermatosis, BRITISH JOURNAL OF DERMATOLOGY, Vol: 187, Pages: E193-E193, ISSN: 0007-0963
- Author Web Link
- Cite
- Citations: 1
Andres MS, Ramalingam S, Rosen SD, et al., 2022, The spectrum of cardiovascular complications related to immune-checkpoint inhibitor treatment Including myocarditis and the new entity of non inflammatory left ventricular dysfunction, CARDIO-ONCOLOGY, Vol: 8
- Author Web Link
- Cite
- Citations: 4
Ramagopalan S, Popat S, Gupta A, et al., 2022, Transportability of Overall Survival Estimates From US to Canadian Patients With Advanced Non-Small Cell Lung Cancer With Implications for Regulatory and Health Technology Assessment, JAMA NETWORK OPEN, Vol: 5, ISSN: 2574-3805
- Author Web Link
- Cite
- Citations: 4
Griesinger F, Popat S, Okhuoya P, et al., 2022, Global real-world (rw) study of patients (pts) with epidermal growth factor receptor (EGFR) mutated advanced non-small cell lung cancer (NSCLC) treated with first-line (1L) osimertinib: Interim analysis of an rw pt registry in Germany, ESMO Asia Congress, Publisher: ELSEVIER, Pages: S1587-S1587, ISSN: 0923-7534
Yang JC-H, Liu G, Lu S, et al., 2022, ALTA-3: A randomized trial of brigatinib (BRG) vs alectinib (ALC) in crizotinib (CRZ)-refractory advanced ALK plus NSCLC, ESMO Asia Congress, Publisher: ELSEVIER, Pages: S1564-S1564, ISSN: 0923-7534
Fendler A, Shepherd STC, Au L, et al., 2022, Functional immune responses against SARS-CoV-2 variants of concern after fourth COVID-19 vaccine dose or infection in patients with blood cancer, Cell Reports Medicine, Vol: 3, ISSN: 2666-3791
Patients with blood cancer continue to have a greater risk of inadequate immune responses following three COVID-19 vaccine doses and risk of severe COVID-19 disease. In the context of the CAPTURE study (NCT03226886), we report immune responses in 80 patients with blood cancer who received a fourth dose of BNT162b2. We measured neutralizing antibody titers (NAbTs) using a live virus microneutralization assay against wild-type (WT), Delta, and Omicron BA.1 and BA.2 and T cell responses against WT and Omicron BA.1 using an activation-induced marker (AIM) assay. The proportion of patients with detectable NAb titers and T cell responses after the fourth vaccine dose increased compared with that after the third vaccine dose. Patients who received B cell-depleting therapies within the 12 months before vaccination have the greatest risk of not having detectable NAbT. In addition, we report immune responses in 57 patients with breakthrough infections after vaccination.
O'Sullivan H, d'Arienzo PD, Yousaf N, et al., 2022, Response to letter entitled: Re: 'Inadequacy of PCR genotyping in advanced non-small cell lung cancer: EGFR L747_A755delinsSS exon 19 deletion is not detected by the real-time PCR Idylla™ EGFR mutation test but is detected by ctDNA NGS and responds to osimertinib' Not looking back, EUROPEAN JOURNAL OF CANCER, Vol: 174, Pages: 318-320, ISSN: 0959-8049
- Author Web Link
- Cite
- Citations: 1
Cho BC, Lin J, Camidge DR, et al., 2022, Pivotal topline data from the phase 1/2 TRIDENT-1 trial of repotrectinib in patients with ROS1+advanced non-small cell lung cancer (NSCLC), EUROPEAN JOURNAL OF CANCER, Vol: 174, Pages: S1-S2, ISSN: 0959-8049
- Author Web Link
- Cite
- Citations: 1
Besse B, Springfeld C, Baik C, et al., 2022, Update from the ongoing phase 1/2 registrational trial of repotrectinib: results in TKI-naive and TKI-pretreated patients with NTRK fusion-positive advanced solid tumors (TRIDENT-1), EUROPEAN JOURNAL OF CANCER, Vol: 174, Pages: S75-S76, ISSN: 0959-8049
Reckamp KL, Lin HM, Cranmer H, et al., 2022, Overall survival indirect treatment comparison between brigatinib and alectinib for the treatment of front-line anaplastic lymphoma kinase-positive non-small cell lung cancer using data from ALEX and final results from ALTA-1L, CURRENT MEDICAL RESEARCH AND OPINION, Vol: 38, Pages: 1587-1593, ISSN: 0300-7995
- Author Web Link
- Cite
- Citations: 1
Begum P, Cui W, Popat S, 2022, Crizotinib-Resistant ROS1 G2101A Mutation Associated With Sensitivity to Lorlatinib in ROS1-Rearranged NSCLC: Case Report., JTO Clin Res Rep, Vol: 3
gene rearrangements occur in 1% to 2% of NSCLC. Acquired "on-target" mutations within the ROS1 kinase domain are a known resistance mechanism to the first-line ROS1 inhibitor crizotinib. Here, we report the first case of a patient with an acquired ROS1 G2101A resistance mutation after first-line crizotinib, who responded to lorlatinib. The response was dramatic but short in duration.
Zhang YZ, Nicholson AG, Ly F, et al., 2022, Prediction of Clinically Significant Pathological Upstaging in Resected Lung Cancer: Insight from COVID-19 Pandemic (1st wave), Publisher: ELSEVIER SCIENCE INC, Pages: S112-S114, ISSN: 1556-0864
McDonald F, Guckenberger M, Popat S, et al., 2022, HALT - Targeted Therapy with or without Dose-Intensified Radiotherapy in Oligo-Progressive Disease in Oncogene Addicted Lung Tumours, Publisher: ELSEVIER SCIENCE INC, Pages: S492-S492, ISSN: 1556-0864
Zhang YZ, Sherlock S, Brambilla C, et al., 2022, Adenocarcinoma Grade Correlates with PD-L1 and TP53, but not EGFR/KRAS Status and Diagnostic Yield: Analysis of 346 Cases, Publisher: ELSEVIER SCIENCE INC, Pages: S516-S517, ISSN: 1556-0864
O'Sullivan HM, MacMahon S, Cui W, et al., 2022, Frequency and Detectability of Uncommon EGFR Mutations in NSCLC, Publisher: ELSEVIER SCIENCE INC, Pages: S88-S89, ISSN: 1556-0864
Garcia Campelo MR, Zhou C, Ramalingam SS, et al., 2022, PRO-CTCAE Analysis of Mobocertinib in EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer (NSCLC), Publisher: ELSEVIER SCIENCE INC, Pages: S487-S488, ISSN: 1556-0864
Eastwood M, Marc ST, Gao X, et al., 2022, MesoGraph: Graph Neural Networks for Weakly Supervised Cellular Profiling in the Subtyping of Malignant Mesothelioma Images, Publisher: ELSEVIER SCIENCE INC, Pages: S331-S332, ISSN: 1556-0864
O'Sullivan HM, MacMahon S, Cunningham N, et al., 2022, Response to Systemic Anti-Cancer Therapy in Uncommon EGFR Mutations, Publisher: ELSEVIER SCIENCE INC, Pages: S430-S430, ISSN: 1556-0864
Begum P, O'Sullvan H, D'Arienzo P, et al., 2022, Lorlatinib Treatment Related Adverse Events: Single Centre Real-World Experience in ALK and ROS1-driven NSCLC, Publisher: ELSEVIER SCIENCE INC, Pages: S461-S462, ISSN: 1556-0864
Griesinger F, Camidge DR, Kim HR, et al., 2022, Final ALTA-1 Results of Brigatinib (BRG) and Crizotinib (CRZ) in ALK Inhibitor-naive Non-small Cell Lung Cancer (NSCLC), Publisher: KARGER, Pages: 103-104, ISSN: 2296-5270
Popat S, Stergiopoulos S, King S, et al., 2022, Indirect treatment comparisons of relative efficacy for aumolertinib vs osimertinib in EGFR-positive non-small cell lung cancer (NSCLC), Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), Publisher: ELSEVIER, Pages: S1012-S1013, ISSN: 0923-7534
Girard N, Popat S, Shoshkova S, et al., 2022, IMreal Cohort 2: Second interim analysis of efficacy and safety data in patients (pts) with locally advanced or metastatic non-small cell lung cancer (NSCLC) receiving atezolizumab (atezo) under real-world conditions, Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), Publisher: ELSEVIER, Pages: S1027-S1028, ISSN: 0923-7534
- Author Web Link
- Cite
- Citations: 2
Farag S, Moore B, Mulla K, et al., 2022, Incidence of clinically relevant hyperglycaemia in patients with non-small cell lung cancer treated with immunotherapy, Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), Publisher: ELSEVIER, Pages: S1081-S1081, ISSN: 0923-7534
Girard N, Popat S, Rahhali N, et al., 2022, Amivantamab compared with European, real-world (RW) standard of care (SoC) in adults with advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) exon 20 insertion mutations (exon20ins), after failure of platinum-based therapy, Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), Publisher: ELSEVIER, Pages: S1062-S1062, ISSN: 0923-7534
Zalcman G, Oulkhouir Y, Cornelissen R, et al., 2022, First-line nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with unresectable malignant pleural mesothelioma (uMPM): 4-year update from CheckMate 743, Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), Publisher: ELSEVIER, Pages: S1438-S1439, ISSN: 0923-7534
- Author Web Link
- Cite
- Citations: 1
Pascual J, Attard G, Bidard F-C, et al., 2022, ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group, ANNALS OF ONCOLOGY, Vol: 33, Pages: 750-768, ISSN: 0923-7534
- Author Web Link
- Cite
- Citations: 94
Cui W, Milner-Watts C, O'Sullivan H, et al., 2022, Up-front cell-free DNA next generation sequencing improves target identification in UK first line advanced non-small cell lung cancer (NSCLC) patients, EUROPEAN JOURNAL OF CANCER, Vol: 171, Pages: 44-54, ISSN: 0959-8049
- Author Web Link
- Cite
- Citations: 10
Banna GL, Addeo A, Zygoura P, et al., 2022, A prognostic score for patients with malignant pleural mesothelioma (MPM) receiving second-line immunotherapy or chemotherapy in the ETOP 9-15 PROMISE-meso phase III trial, LUNG CANCER, Vol: 169, Pages: 77-83, ISSN: 0169-5002
- Author Web Link
- Cite
- Citations: 1
Miura S, Schuler M, Popat S, et al., 2022, A database of 1023 patients with NSCLC and uncommon <i>EGFR</i> mutations treated with afatinib: focus on Asian patients, 19th Annual Meeting of the Japanese-Society-of-Medical-Oncology (JSMO), Publisher: ELSEVIER, Pages: S500-S500, ISSN: 0923-7534
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.